ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

ClinicalTrials.gov ID: NCT03610581

Public ClinicalTrials.gov record NCT03610581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix

Study identification

NCT ID
NCT03610581
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Enrollment
9 participants

Conditions and interventions

Interventions

  • Ad26.HPV16 Biological
  • Ad26.HPV18 Biological
  • MVA.HPV16/18 Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 26, 2018
Primary completion
Oct 14, 2020
Completion
Oct 14, 2020
Last update posted
Feb 3, 2025

2018 – 2020

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
Doral Medical Research Doral Florida 33166
Clinical Physiology Associates Fort Myers Florida 33912
Florida Research Center Inc. Miami Florida 33174
San Marcus Research Clinic, Inc. Miami Lakes Florida 33014
University of Iowa Hospital Iowa City Iowa 52242
University of Kansas Medical Center Kansas City Kansas 66160
Heartland Research Associates, LLC Newton Kansas 67114
Medpharmics, LLC Metairie Louisiana 70006
Meridian Clinical Research, LLC Norfolk Nebraska 68701
Columbia University Medical Center New York New York 10032
VGR & NOCCR - Knoxville Knoxville Tennessee 37920

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03610581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 3, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03610581 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →